649 related articles for article (PubMed ID: 35137006)
1. Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant.
Risk M; Shen C; Hayek SS; Holevinski L; Schiopu E; Freed G; Akin C; Zhao L
Clin Infect Dis; 2022 Aug; 75(1):e623-e629. PubMed ID: 35137006
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina.
Lin DY; Gu Y; Wheeler B; Young H; Holloway S; Sunny SK; Moore Z; Zeng D
N Engl J Med; 2022 Mar; 386(10):933-941. PubMed ID: 35020982
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of mRNA-based BNT162b2 Vaccine versus Adenovirus Vector-Based Ad26.COV2.S Vaccine for the Prevention of COVID-19 among Dialysis Patients.
Brunelli SM; Sibbel S; Karpinski S; Marlowe G; Walker AG; Giullian J; Van Wyck D; Kelley T; Lazar R; Zywno ML; Connaire JJ; Young A; Tentori F
J Am Soc Nephrol; 2022 Apr; 33(4):688-697. PubMed ID: 35135894
[TBL] [Abstract][Full Text] [Related]
4. Covid-19 Vaccine Effectiveness in New York State.
Rosenberg ES; Dorabawila V; Easton D; Bauer UE; Kumar J; Hoen R; Hoefer D; Wu M; Lutterloh E; Conroy MB; Greene D; Zucker HA
N Engl J Med; 2022 Jan; 386(2):116-127. PubMed ID: 34942067
[TBL] [Abstract][Full Text] [Related]
5. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers.
Brunner WM; Freilich D; Victory J; Krupa N; Scribani MB; Jenkins P; Lasher EG; Fink A; Shah A; Cross P; Bush V; Peek LJ; Pestano GA; Gadomski AM
Int J Infect Dis; 2022 Oct; 123():183-191. PubMed ID: 36044963
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting.
Rane MS; Robertson MM; Kulkarni SG; Frogel D; Gainus C; Nash D
Vaccine; 2023 Jan; 41(4):989-998. PubMed ID: 36588007
[TBL] [Abstract][Full Text] [Related]
7. Adverse outcomes of SARS-CoV-2 infection with delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study.
Bohnert AS; Kumbier K; Rowneki M; Gupta A; Bajema K; Hynes DM; Viglianti E; O'Hare AM; Osborne T; Boyko EJ; Young-Xu Y; Iwashyna TJ; Maciejewski M; Schildhouse R; Dimcheff D; Ioannou GN
BMJ; 2023 May; 381():e074521. PubMed ID: 37220941
[TBL] [Abstract][Full Text] [Related]
8. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of a nationwide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: a retrospective analysis of national surveillance data.
Bello-Chavolla OY; Antonio-Villa NE; Valdés-Ferrer SI; Fermín-Martínez CA; Fernández-Chirino L; Vargas-Vázquez A; Ramírez-García D; Mancilla-Galindo J; Kammar-García A; Ávila-Funes JA; Zúñiga-Gil CH; García-Grimshaw M; Ceballos-Liceaga SE; Carbajal-Sandoval G; Montes-González JA; Zaragoza-Jiménez CA; García-Rodríguez G; Cortés-Alcalá R; Reyes-Terán G; López-Gatell H; Gutiérrez-Robledo LM
Int J Infect Dis; 2023 Apr; 129():188-196. PubMed ID: 36775188
[TBL] [Abstract][Full Text] [Related]
10. Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines.
Naranbhai V; Garcia-Beltran WF; Chang CC; Berrios Mairena C; Thierauf JC; Kirkpatrick G; Onozato ML; Cheng J; St Denis KJ; Lam EC; Kaseke C; Tano-Menka R; Yang D; Pavlovic M; Yang W; Kui A; Miller TE; Astudillo MG; Cahill JE; Dighe AS; Gregory DJ; Poznansky MC; Gaiha GD; Balazs AB; Iafrate AJ
J Infect Dis; 2022 Apr; 225(7):1141-1150. PubMed ID: 34888672
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines.
Kelly JD; Leonard S; Hoggatt KJ; Boscardin WJ; Lum EN; Moss-Vazquez TA; Andino R; Wong JK; Byers A; Bravata DM; Tien PC; Keyhani S
JAMA; 2022 Oct; 328(14):1427-1437. PubMed ID: 36156706
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of various COVID-19 vaccine regimens among 10.4 million patients from the National COVID Cohort Collaborative during Pre-Delta to Omicron periods - United States, 11 December 2020 to 30 June 2022.
Fu Y; Wu K; Wang Z; Yang H; Chen Y; Wu L; Yanagihara R; Hedges JR; Wang H; Deng Y;
Vaccine; 2023 Oct; 41(42):6339-6349. PubMed ID: 37741761
[TBL] [Abstract][Full Text] [Related]
13. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States.
Abara WE; Gee J; Marquez P; Woo J; Myers TR; DeSantis A; Baumblatt JAG; Woo EJ; Thompson D; Nair N; Su JR; Shimabukuro TT; Shay DK
JAMA Netw Open; 2023 Feb; 6(2):e2253845. PubMed ID: 36723942
[TBL] [Abstract][Full Text] [Related]
14. Durability of the Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge.
Polinski JM; Weckstein AR; Batech M; Kabelac C; Kamath T; Harvey R; Jain S; Rassen JA; Khan N; Schneeweiss S
JAMA Netw Open; 2022 Mar; 5(3):e222959. PubMed ID: 35297969
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of COVID-19 vaccines in patients taking immunosuppressants.
Shen C; Risk M; Schiopu E; Hayek SS; Xie T; Holevinski L; Akin C; Freed G; Zhao L
Ann Rheum Dis; 2022 Jun; 81(6):875-880. PubMed ID: 35197265
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
Cerqueira-Silva T; Andrews JR; Boaventura VS; Ranzani OT; de Araújo Oliveira V; Paixão ES; Júnior JB; Machado TM; Hitchings MDT; Dorion M; Lind ML; Penna GO; Cummings DAT; Dean NE; Werneck GL; Pearce N; Barreto ML; Ko AI; Croda J; Barral-Netto M
Lancet Infect Dis; 2022 Jun; 22(6):791-801. PubMed ID: 35366959
[TBL] [Abstract][Full Text] [Related]
17. Vaccine-Associated Uveitis after COVID-19 Vaccination: Vaccine Adverse Event Reporting System Database Analysis.
Singh RB; Parmar UPS; Kahale F; Agarwal A; Tsui E
Ophthalmology; 2023 Feb; 130(2):179-186. PubMed ID: 36055601
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness and duration of protection of ChAdOx1, CoronaVac, BNT162b2, mRNA-1273, and Ad26.COV2.S COVID-19 vaccines for symptomatic and hospitalized Mu, Delta, and Omicron: A test-negative case-control study.
Paternina-Caicedo A; Quevedo DS; Ríos DS; Moyano D; Alvis-Guzmán N; Alviz-Zakzuk NR; Salcedo F; Moyano L; Ramírez-Suarez J; Smith AD; De la Hoz-Restrepo F
Vaccine; 2023 Oct; 41(42):6291-6299. PubMed ID: 37679278
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines.
Zhang GF; Meng W; Chen L; Ding L; Feng J; Perez J; Ali A; Sun S; Liu Z; Huang Y; Guo H; Gao SJ
J Med Virol; 2022 Dec; 94(12):5678-5690. PubMed ID: 35902378
[TBL] [Abstract][Full Text] [Related]
20. Homologous and Heterologous Covid-19 Booster Vaccinations.
Atmar RL; Lyke KE; Deming ME; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Posavad CM; Archer JI; Crandon S; Nayak SU; Szydlo D; Zemanek JA; Dominguez Islas CP; Brown ER; Suthar MS; McElrath MJ; McDermott AB; O'Connell SE; Montefiori DC; Eaton A; Neuzil KM; Stephens DS; Roberts PC; Beigel JH;
N Engl J Med; 2022 Mar; 386(11):1046-1057. PubMed ID: 35081293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
